Food, Drugs, Healthcare, Life Sciences

Subscribe
Welcome to the Mondaq Food, Drugs, Healthcare, Life Sciences homepage, here you will find thought leadership articles, podcasts, videos and webinars providing insights covering topics such as Food and Drugs Law, Healthcare, Life Sciences, Biotechnology and Nanotechnology.
Article
EU Council Adopts New EU Pharma Package
The Council of the EU has adopted the most comprehensive reform of EU pharmaceutical legislation in over 20 years, fundamentally reshaping regulatory protection mechanisms, market exclusivity periods, and incentive structures for pharmaceutical companies. These reforms balance patient access to medicines with creating a more competitive and innovation-friendly environment, addressing antimicrobial resistance, medicine supply challenges, and the early availability of generic alternatives.
Ireland Healthcare
M
Matheson
Article
EU Pharma Package: New Incentives For Innovation In Antibiotics
The EU Pharma Package introduces a novel approach to combat antimicrobial resistance through transferable exclusivity vouchers that reward innovation in priority antimicrobials while simultaneously implementing stricter antibiotic stewardship measures. This regulatory framework attempts to resolve the fundamental tension between incentivizing pharmaceutical companies to develop new antibiotics and ensuring these critical medicines are used prudently to prevent further resistance development.
European Union Healthcare
CMS Wistrand
See more

Webinars

See More

Food and Drugs Law

Article
EU Council Adopts New EU Pharma Package
The Council of the EU has adopted the most comprehensive reform of EU pharmaceutical legislation in over 20 years, fundamentally reshaping regulatory protection mechanisms, market exclusivity periods, and incentive structures for pharmaceutical companies. These reforms balance patient access to medicines with creating a more competitive and innovation-friendly environment, addressing antimicrobial resistance, medicine supply challenges, and the early availability of generic alternatives.
Ireland Healthcare
M
Matheson
See more

Life Sciences, Biotechnology & Nanotechnology

Article
EU Council Adopts New EU Pharma Package
The Council of the EU has adopted the most comprehensive reform of EU pharmaceutical legislation in over 20 years, fundamentally reshaping regulatory protection mechanisms, market exclusivity periods, and incentive structures for pharmaceutical companies. These reforms balance patient access to medicines with creating a more competitive and innovation-friendly environment, addressing antimicrobial resistance, medicine supply challenges, and the early availability of generic alternatives.
Ireland Healthcare
M
Matheson
Article
Miniaturisation And Patentability: Why Scaling Down A Product Is Not Enough To Qualify As A Patentable Invention
Modern engineering increasingly prioritizes making products smaller, lighter, and more portable, but does miniaturization alone constitute a patentable invention? Patent law requires more than impressive size reduction—it demands non-obvious technical solutions to specific problems created by scaling down, such as thermal management, signal integrity, or mechanical stress challenges.
France IP
HL
HGF Ltd
See more

Healthcare

Article
EU Council Adopts New EU Pharma Package
The Council of the EU has adopted the most comprehensive reform of EU pharmaceutical legislation in over 20 years, fundamentally reshaping regulatory protection mechanisms, market exclusivity periods, and incentive structures for pharmaceutical companies. These reforms balance patient access to medicines with creating a more competitive and innovation-friendly environment, addressing antimicrobial resistance, medicine supply challenges, and the early availability of generic alternatives.
Ireland Healthcare
M
Matheson
Article
Pseudonymised, Not Anonymous: What The Italian Garante’s €7 Million IQVIA Fine Means For Health Data
The Italian data protection authority fined IQVIA Solutions Italy €7 million for treating patient records as anonymous when they were actually pseudonymised personal data subject to GDPR. This decision demonstrates regulators' strict interpretation of what constitutes personal data, even as the EU considers narrowing this definition through the Digital Omnibus reforms.
Global Privacy
AP
Arnold & Porter
See more

Latest Videos

See more